59115
document
Prevalence and treatment outcome of cervicitis of unknown etiology . BACKGROUND Mucopurulent cervicitis ( MPC ) is a clinical syndrome characterized by mucopurulent discharge from the cervix and other signs of inflammation . This was a phase III , multicenter study designed to evaluate the effectiveness of placebo versus empiric antibiotic treatment for clinical cure of MPC of unknown etiology at 2-month follow-up . Unfortunately , enrollment was terminated because of low accrual of women with cervicitis of unknown etiology , but important prevalence and outcome data were obtained . METHODS Five hundred seventy-seven women were screened for MPC . Women with MPC were randomized to the treatment or placebo arm of the study , and the 2 arms were evaluated based on the etiology , clinical cure rates , adverse events ( AEs ) , and rates of pelvic inflammatory disease . RESULTS One hundred thirty-one ( 23 % [ 131/577 ] ) screened women were found to have MPC . Eighty-seven were enrolled and randomized . After excluding women with sexually transmitted infections and other exclusions , 61 % ( 53/87 ) had cervicitis of unknown etiology . The overall clinical failure rate was 30 % ( 10/33 ) , and the clinical cure rate was only 24 % ( 8/33 ) . Rates were not significantly different between the arms . There were 24 gastrointestinal AEs in the treatment arm compared with 1 AE in the placebo arm . CONCLUSIONS More than half of the cases of MPC were of unknown etiology . Clinical cure rates for the placebo and treatment arms were extremely low , with most women concluding the study with a partial response . Gastrointestinal AEs were higher in the treatment arm .
59116
Intervention_Control
placebo
59117
Intervention_Pharmacological
empiric antibiotic treatment
59118
Intervention_Control
placebo
59119
Intervention_Control
placebo
59120
Intervention_Control
placebo
59121
Outcome_Physical
cervicitis
59122
Outcome_Physical
MPC
59123
Outcome_Other
clinical cure rates
59124
Outcome_Adverse-effects
adverse events ( AEs )
59125
Outcome_Physical
rates of pelvic inflammatory disease
59126
Outcome_Physical
cervicitis
59127
Outcome_Other
overall clinical failure rate
59128
Outcome_Other
clinical cure rate
59129
Outcome_Adverse-effects
gastrointestinal AEs
59130
Outcome_Other
Clinical cure rates
59131
Outcome_Adverse-effects
Gastrointestinal AEs
59132
Participant_Condition
cervicitis
59133
Participant_Sex
women
59134
Participant_Sample-size
Five hundred seventy-seven
59135
Participant_Condition
MPC .
59136
Participant_Sample-size
One hundred thirty-one
59137
Participant_Sample-size
Eighty-seven